Stock Movers

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- JD Sports cut its profit outlook after weaker-than-expected sales of sneakers in the second quarter, as its customers grapple with cost-of-living pressures and pull back on discretionary spending.
- Novonesis jumped to a more than one-year high in Copenhagen trading after the world’s largest maker of industrial enzymes raised its financial forecast and said it will buy back own stock for the first time.
- Sartorius rises as much as 5.9%, the most in six weeks, after the stock was upgraded to buy from neutral at UBS. The German lab equipment maker is “well-positioned for accelerating growth” from 2027 to 2029, according to the broker.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- After SK Hynix unveiled its own program to buy back 40 trillion won ($29 billion) of stock, JPMorgan Chase & Co. said the company may follow that up with additional returns worth at least $130 billion. SK Hynix rose as much as 14.7%.
- Kuaishou Tech shares drop as much as 12% in Hong Kong after the Chinese Internet firm gave weak guidance for the coming quarter that triggered a wave of analyst downgrades over concerns around weak macro conditions and policy tightening on online-streaming e-commerce.
- Sino Biopharmaceutical and Asian healthcare firms are rising on the back of a skin cancer vaccine trial breakthrough by Moderna and Merck.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market, a look at the notable movers:
On this episode of Stock Movers:

-Moderna (MRNA) shares surged, delivering a $5.5 billion blow to short sellers who had bet that the vaccine maker's slump would continue. The company's stock price soared 177% after it said its personalized cancer vaccine helped reduce the recurrence of melanoma in a late-stage trial. The jump generated paper losses of about $5.5 billion for short sellers, bringing mark-to-market losses to roughly $7.7 billion this year, according to data from S3 Partners LLC.

- SK Hynix (KS) unveiled plans to buy back 40 trillion won of shares and return more profits to investors, moving to stabilize its shares after they fell more than 50% in two months. The memory chipmaker will buy back as many as 24 million shares between Aug. 20 and Nov. 19 and cancel them, and raised its shareholder return pledge to more than 50% of cumulative free cash flow from 2025 to 2027. SK Hynix’s buyback plan is partly aimed at appeasing Korean retail investors who were upset by the company’s decision to issue new shares for its US listing, rather than through existing treasury stock, which diluted their local holdings.

- Estée Lauder (EL) shares jumped after its results beat estimates and ended a run of three straight declines in annual revenue. The company reported revenue of $3.6 billion in its fiscal fourth quarter and adjusted earnings per share of $0.39, which topped expectations. The company reaffirmed guidance for organic net sales growth and raised guidance on its adjusted operating margin, with analysts saying a steady recovery is underway.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:

Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Isabelle Lee, Carol Massar and Emily Graffeo

- Moderna (MRNA) shares surged, delivering a $5.5 billion blow to short sellers who had bet that the vaccine maker's slump would continue. The company's stock price soared 177% after it said its personalized cancer vaccine helped reduce the recurrence of melanoma in a late-stage trial. The jump generated paper losses of about $5.5 billion for short sellers, bringing mark-to-market losses to roughly $7.7 billion this year, according to data from S3 Partners LLC.

- Estée Lauder (EL) shares jumped after its results beat estimates and ended a run of three straight declines in annual revenue. The company reported revenue of $3.6 billion in its fiscal fourth quarter and adjusted earnings per share of $0.39, which topped expectations. The company reaffirmed guidance for organic net sales growth and raised guidance on its adjusted operating margin, with analysts saying a steady recovery is underway.

- TJ Maxx (TJX) shares fall 0.84% in Wednesday trading after the clothing retailer reported second-quarter comparable sales for its Marmaxx segment, which includes TJ Maxx and Marshalls, that missed the average analyst estimate.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:

-SK Hynix ADRs rose. SK Hynix Inc. unveiled plans to buy back 40 trillion won ($29 billion) of shares and return more profits to investors, moving to stabilize its shares after they fell more than 50% in two months. The memory chipmaker said it will buy back as many as 24 million shares between Aug. 20 and Nov. 19 and cancel them, according to a regulatory filing Wednesday. It also raised its shareholder return pledge to more than 50% of cumulative free cash flow from 2025 to 2027, equivalent to about $170 billion, according to Bloomberg calculations.

 
-Moderna (MRNA) shares rise. A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone. The companies will discuss filing for approval with regulators and will present the data at an upcoming medical meeting, with Moderna Chief Executive Officer Stéphane Bancel saying the product could be approved as soon as 2027.

-Estee Lauder (EL) shares jumped after its results beat estimates and ended a run of three straight declines in annual revenue. The company reported revenue of $3.6 billion in its fiscal fourth quarter and organic sales growth accelerated to 5%. The company reaffirmed guidance for organic net sales growth of 3% to 5% in its current fiscal year, and raised guidance on its adjusted operating margin.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Moderna (MRNA) shares rise. A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone. The companies will discuss filing for approval with regulators and will present the data at an upcoming medical meeting, with Moderna Chief Executive Officer Stéphane Bancel saying the product could be approved as soon as 2027.
- La-Z Boy (LZB) shares tumble after the furniture maker’s forecast sales for the second quarter missed the average analyst estimate. KeyBanc Capital Markets analyst Bradley Thomas says the company “issued F2Q sales and implied EPS guidance below consensus, pressured in part by continued investments”
- Norfolk Southern Corp (NSC) climbs after a federal regulator resumed its review of Union Pacific’s bid for the rival. The Surface Transportation Board established a procedural schedule for public comment, with participants having until Sept. 4 to file a notice of intent to participate in the review process.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- Shares of Moderna (MRNA) surged by a record 101% - the stock’s biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.’s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday.

- Shares of Estee Lauder (EL) rallied after the beauty company’s adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views.

- Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker’s forecast sales for the second quarter missed the average analyst estimate.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Shares of Target Corp. (TGT) dipped in the early session. That's despite the retail giant reported comparable sales for the second quarter that beat the average analyst estimate. The company also lifted its full-year guidance after results outpaced estimates in the latest quarter, suggesting the big-box retailer is moving past a lengthy sales slump. The company now expects net sales to increase about 5% in the current fiscal year, which ends in early 2027 — a percentage point higher than the previous guidance.
- Shares of Lowe's Cos. (LOW) slipped in premarket trading after the company cut its outlook for the full year after posting results that missed Wall Street estimates, showing how a stubbornly weak housing market is eroding the home-improvement retailer’s performance. The company now expects comparable sales to be flat this fiscal year, after previously forecasting as much as 2% growth. Comparable sales, which measure results at locations open at least a year, grew 0.2% in the second quarter, missing the average of estimates compiled by Bloomberg.
- Shares of Moderna (MRNA) surged as much as 80% in premarket trading  after the company joined Merck (MRK) to announce their personalized cancer vaccine helped cut the recurrence of melanoma in a large, late-stage trial - an important milestone for the mRNA-based therapy. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, could lower the rate of melanoma recurrence, compared with the immunotherapy alone. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Trainline shares fell as much as 17%, the most in five years, after the UK competition watchdog opened an investigation into whether the rail-booking platform breached consumer law through “drip pricing.”
- Smith & Nephew shares drop to the lowest intraday level since May 12 after the medical devices maker said chief financial officer John Rogers will leave his position at the end of next month. Analysts suggest his departure will raise questions about the company’s outlook.
- Straumann drops as much as 9.1%, the most in a year, after the Swiss dental implant maker said Christopher Norbye would replace Guillaume Daniellot as CEO. Analysts at Bernstein and JPMorgan said Daniellot was “well-liked,” with the news overshadowing the better-than-expected earnings for the first half-year.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Carlsberg volume growth was softer than expected in the first half, as subdued beer demand in Europe and Asia undermined a strong performance in soft drinks.
- Shares in Frontline PLC which owns a fleet of large crude carriers are benefiting from elevated crude tanker rates due to uncertainty in the Strait of Hormuz.
- Smith & Nephew shares drop as much as 3.7% to the lowest intraday level since May 12 after the medical devices maker said chief financial officer John Rogers will leave his position at the end of next month. Analysts suggest his departure will raise questions about the company’s outlook.

See omnystudio.com/listener for privacy information.